Companies › Atrium Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout May 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ATR 1072 siRNA targeting PRKAG2 to reduce gene expression | PRKAG2 | Phase 1 | Cardiac Glycogenosis | May 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07738107 | ATR 1072 | Phase 1 | Cardiac Glycogenosis | Cardiovascular | May 2028 |
Cash and short-term investments of $264m on 2026-06-30; operating cash outflow about $71m a year; runway about 44 months at that burn, to Mar 2030
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.